Main clinicobiological features of stereotyped subset #2 and non–subset #2/IGHV3-21 cases included in the survival analysis
| . | Subset #2 (n = 212) . | Non–subset #2/ IGHV3-21 (n = 143) . | P . |
|---|---|---|---|
| Male | 132/254, 62% | 87/183, 61% | ns |
| Age (median) | 63.5 y | 62.2 y | ns |
| Binet A | 72/156, 46% | 50/81, 61% | .023 |
| U-CLL | 86/212, 40% | 84/143, 59% | .0007 |
| CD38 expression | 35/92, 38% | 31/73, 42% | ns |
| ZAP70 expression | 23/54, 43% | 16/33, 48% | ns |
| del(13q) | 50/81, 61% | 27/51, 53% | ns |
| Trisomy 12 | 5/103, 5% | 5/65, 8% | ns |
| del(11q) | 23/109, 21% | 10/70, 14% | ns |
| del(17p) | 4/103, 4% | 3/69, 4% | ns |
| TTFT | 22 mo | 60 mo | .001 |
| TTFT (M-CLL) | 23 mo | 154 mo | <.0001 |
| TTFT (U-CLL) | 19 mo | 30 mo | ns |
| . | Subset #2 (n = 212) . | Non–subset #2/ IGHV3-21 (n = 143) . | P . |
|---|---|---|---|
| Male | 132/254, 62% | 87/183, 61% | ns |
| Age (median) | 63.5 y | 62.2 y | ns |
| Binet A | 72/156, 46% | 50/81, 61% | .023 |
| U-CLL | 86/212, 40% | 84/143, 59% | .0007 |
| CD38 expression | 35/92, 38% | 31/73, 42% | ns |
| ZAP70 expression | 23/54, 43% | 16/33, 48% | ns |
| del(13q) | 50/81, 61% | 27/51, 53% | ns |
| Trisomy 12 | 5/103, 5% | 5/65, 8% | ns |
| del(11q) | 23/109, 21% | 10/70, 14% | ns |
| del(17p) | 4/103, 4% | 3/69, 4% | ns |
| TTFT | 22 mo | 60 mo | .001 |
| TTFT (M-CLL) | 23 mo | 154 mo | <.0001 |
| TTFT (U-CLL) | 19 mo | 30 mo | ns |
del(13q): isolated deletion of chromosome 13q; ns: nonsignificant. P values in bold indicate statistically significant differences.